The Medical Letter on Drugs and Therapeutics
June 22, 2015
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Liraglutide (Saxenda) for Weight Loss
June 22, 2015 (Issue: 1471)The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza, has now also been approved at a higher dose as Saxenda (Novo Nordisk) for chronic weight...more
- Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010; 52:25.
- Diet, drugs, and surgery for weight loss. Med Lett Drugs Ther 2015; 57:21.
- Two drugs for weight loss. Med Lett Drugs Ther 2012; 54:69.
- Contrave – a combination of bupropion and naltrexone for weight loss. Med Lett Drugs Ther 2014; 56:112.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.